Source-grounded facts extracted from Lifeward Ltd.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lifeward Ltd. issued warrant to Oramed and certain investors.
“On March 25, 2026, the Company issued: (i) $10,000,000.00 aggregate principal amount senior secured convertible notes (the “Initial Notes”), convertible into Ordinary Shares, and (ii) accompanying warrants to purchase Ordinary Shares (the “Initial Warrants”).”
Lifeward Ltd. issued convertible note to Oramed and certain investors for $10,000,000.00 aggregate principal amount.
“On March 25, 2026, the Company issued: (i) $10,000,000.00 aggregate principal amount senior secured convertible notes (the “Initial Notes”), convertible into Ordinary Shares, and (ii) accompanying warrants to purchase Ordinary Shares (the “Initial Warrants”).”
Lifeward Ltd. completed an acquisition involving Oramed Pharmaceuticals, Inc. (closed 2026-03-25).
“On March 25, 2026, the Company completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement.”
Lifeward Ltd. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)).
“March 17, 2026, Lifeward Ltd. (the “Company”) received a notice (the “Audit Committee Notice”) from the Nasdaq Listing Qualifications Department indicating that, following Hadar Levy’s resignation from the Board of Directors of the Company, which reduced the Audit Committee to two members, the Company no longer complies with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A), which requires listed companies to have an audit committee of at least three members. The Company is in the process of reviewing and evaluating potential options to regain compliance with these con”
Lifeward Ltd. reported financial results for the fourth quarter and fiscal year ended December 31, 2025.
“On March 18, 2026, Lifeward Ltd. (the “Company,” “we” or “us”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025.”
Lifeward Ltd.: Adopted Eighth Amended and Restated Articles of Association to effect a 1-for-12 reverse share split and increase authorized ordinary shares from 75,000,000 to 100,000,000 (effective 2026-02-24).
“On February 24, 2026 (the “Effective Date”), Lifeward Ltd. (the “Company”) effected a 1-for-12 reverse share split (the “Reverse Split”) of all of the Company’s ordinary shares, no par value per share (the “Ordinary Shares”), and, in connection therewith, adopted its Eighth Amended and Restated Articles of Association (the “Articles”).”
Lifeward Ltd. incurred loan of initial principal amount of $525,000 with Oramed Pharmaceuticals, Inc. at 24% per annum maturing the earlier of (i) August 12, 2026 and (ii) the failure of the Company to obtain shareholder approval.
“On February 12, 2026, the Company entered into a Secured Promissory Note (the “Subsequent Secured Promissory Note”) with Oramed Pharmaceuticals, Inc. (“Oramed”) pursuant to which the Company issued to Oramed a secured promissory note in the initial principal amount of $525,000”
Lifeward Ltd. entered into Subsequent Secured Promissory Note with Oramed Pharmaceuticals, Inc. valued at initial principal amount of $525,000, which amount may be increased by up to an additional $975,000 (effective 2026-02-12).
“On February 12, 2026, the Company entered into a Secured Promissory Note (the “Subsequent Secured Promissory Note”) with Oramed Pharmaceuticals, Inc. (“Oramed”) pursuant to which the Company issued to Oramed a secured promissory note in the initial principal amount of $525,000, which amount may be increased by up to an additional $975,000 upon the mutual consent of the parties.”
Lifeward Ltd. entered into Share Purchase Agreement with Oramed Pharmaceuticals, Inc. (effective 2026-01-12).
“On January 12, 2026, Lifeward Ltd. (the “Company,” “we” or “us”) entered into a Share Purchase Agreement (“Share Purchase Agreement”) with Oramed Pharmaceuticals, Inc. (“Oramed”) and Oratech Pharma, Inc. (“Oratech”) pursuant to which the Company agreed to acquire all of the outstanding equity interests in Oratech, a wholly owned subsidiary of Oramed (the “Oratech Share Purchase”).”
Lifeward Ltd. incurred loan of $3.0 million with Oramed Ltd. at 15% per annum maturing May 14, 2026.
“On November 14, 2025, Lifeward Ltd. (the “Company,” “we” or “us”) entered into a Secured Promissory Note (the “Secured Promissory Note”) with Oramed Ltd. (“Oramed”) pursuant to which, we issued to Oramed a secured promissory note in the principal amount of $3.0 million.”
Larry Jasinski resigned as Director at Lifeward Ltd..
“Larry Jasinski, a member of the Board and the Company’s Co-Chief Executive Officer, notified the Board of his decision to resign as a member of the Board, effective as of June 30, 2025.”
Mark Grant was appointed as Director at Lifeward Ltd..
“appointed Mark Grant as a Class II director, effective June 15, 2025.”
Michael Lawless resigned as Chief Financial Officer at Lifeward Ltd..
“On June 2, 2025, Michael Lawless notified Lifeward Ltd. (the “ Company ”) of his resignation as Chief Financial Officer and Principal Financial Officer, effective as of June 27, 2025 or such earlier date as agreed upon by the Company and Mr. Lawless.”
Mark Grant was appointed as President and Chief Executive Officer at Lifeward Ltd..
“the Board of Directors (the “Board”) of Lifeward Ltd. (the “Company”) approved the appointment of Mark Grant as the Company’s President and Chief Executive Officer, effective June 2, 2025”
Charles Remsberg was terminated as Chief Sales Officer at Lifeward Ltd..
“Pursuant to notice provided on April 8, 2025, Charles Remsberg’s employment as the Chief Sales Officer of the Company will be terminated, effective May 30, 2025.”
Larry Jasinski departed as Chief Executive Officer at Lifeward Ltd..
“On February 19, 2025, the Company announced that Larry Jasinski will step down as the Chief Executive Officer of the Company and member of the Board of Directors of the Company (the “Board”), by the end of the second quarter of 2025.”
Robert J. Marshall Jr. was appointed as Director at Lifeward Ltd..
“appointed Robert J. Marshall Jr. to serve as a member of the Board, effective as of November 2, 2024”
Joseph Turk was appointed as Chairperson of the Board at Lifeward Ltd..
“On June 27, 2024, the Board approved the appointment of Joseph Turk as chairperson of the Board, effective as of the Annual Meeting.”
Jeff Dykan retired as Chairperson of the Board at Lifeward Ltd..
“On June 27, 2024, Jeff Dykan, current Class I director of the Board of Directors (the “Board”) of ReWalk Robotics, Ltd. (the “Company”) and chairperson of the Board, notified the Board that he will retire and not stand for reelection at the Company’s 2024 Annual General Meeting of Shareholders (the “Annual Meeting”).”
Lifeward Ltd. reported the three months ended March 31, 2024 results: revenue $5.3 million, net income Net loss was $6.3 million, or $0.73 per share, EPS $0.73 per share. Guidance reaffirmed.
“MACs will enable us to further our mission of broader access to innovative exoskeleton technology for appropriate individuals.” First Quarter 2024 Financial Results Revenue was $5.3 million in the first quarter of 2024, compared to $1.2 million during the first quarter of 2023, up $4.1 million, or 340%. Revenue from the sale of products from the former ReWalk”
Michael Swinford was appointed as Class III director at Lifeward Ltd..
“On April 18, 2024, the Board of Directors (the “Board”) of ReWalk Robotics Ltd. (the “Company”) increased the size of the Board from six (6) to seven (7) members, and appointed Michael Swinford to serve as a member of the Board, effective immediately.”
Lifeward Ltd. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
“On February 27, 2024, ReWalk Robotics Ltd. (the "Company," "we" or "us") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
Lifeward Ltd. reported third quarter ended September 30, 2023 results: revenue $4.4 million, net income $7.5 million, or $(0.13) per share, EPS $(0.13) per share.
“Total revenue was $4.4 million in the third quarter of 2023, compared to $0.9 million during the third quarter of 2022”
Lifeward Ltd. shareholders rejected To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to Item 402 of Regulation S-K of the SEC, including the compensation tables and accompanying narrative disclosures.
“Proposal No. 8: To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to Item 402 of Regulation S-K of the SEC, including the compensation tables and accompanying narrative disclosures. For Against Abstain Broker Non-Votes 4,108,344 11,613,202 936,181 13,704,575”
Lifeward Ltd. shareholders approved To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2023 and until the next annual meeting of shareholders, and to authorize the Board, upon recommendation of t at the 2023-12-31 meeting.
“Proposal No. 7: To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2023 and until the next annual meeting of shareholders, and to authorize the Board, upon recommendation of the audit committee, to fix the remuneration of said independent registered public accounting firm . For Against Abstain 28,619,227 1,563,077 179,997”
Lifeward Ltd. shareholders approved Subject to the approval of Proposal 5, and if the Board determines to effect a reverse share split pursuant thereto, to approve amendments to the Company’s Articles of Association authorizing an increase in the Company’s authorized share capital.
“Proposal No. 6: Subject to the approval of Proposal 5, and if the Board determines to effect a reverse share split pursuant thereto, to approve amendments to the Company’s Articles of Association authorizing an increase in the Company’s authorized share capital . For Against Abstain Broker Non-Votes 24,525,820 4,914,424 922,055 —”
Lifeward Ltd. shareholders approved To authorize the Board to determine whether to effect a reverse share split of the Company’s outstanding ordinary shares, par value NIS 0.25 each, and if so, to set a ratio within a range of 1-for-2 to 1-for-12, to be effective on a date to be determined by the Board, and to approve conforming amend.
“Proposal No. 5: To authorize the Board to determine whether to effect a reverse share split of the Company’s outstanding ordinary shares, par value NIS 0.25 each, and if so, to set a ratio within a range of 1-for-2 to 1-for-12, to be effective on a date to be determined by the Board, and to approve conforming amendments to the Company’s Articles of Association to reflect any such reverse share split . For Against Abstain Broker Non-Votes 26,454,420 3,794,752 113,127 —”
Lifeward Ltd. shareholders approved To approve the Company’s restated Compensation Policy for directors and officers.
“Proposal No. 4: To approve the Company’s restated Compensation Policy for directors and officers. For Against Abstain Broker Non-Votes 4,819,032 1,760,888 10,077,808 13,704,575”
Lifeward Ltd. shareholders approved To approve the extension of the term of the Consulting Agreement with Richner Consultants, LLC, a Delaware company owned by Randel E. Richner, a member of the Board.
“Proposal No. 3: To approve the extension of the term of the Consulting Agreement with Richner Consultants, LLC, a Delaware company owned by Randel E. Richner, a member of the Board . For Against Abstain Broker Non-Votes 14,966,985 1,004,515 686,227 13,704,575”
Lifeward Ltd. shareholders approved To approve (i) a one-time grant of 200,000 RSUs to Larry Jasinski, the Company’s CEO, and (ii) an increase in Mr. Jasinski’s annual salary by five and one-half percent (5.5%), effective January 1, 2023 at the 2023-01-01 meeting.
“Proposal No. 2.: To approve (i) a one-time grant of 200,000 RSUs to Larry Jasinski, the Company’s CEO, and (ii) an increase in Mr. Jasinski’s annual salary by five and one-half percent (5.5%), effective January 1, 2023. For Against Abstain Broker Non-Votes 4,346,554 2,421,327 9,889,846 13,704,575”
Lifeward Ltd. shareholders rejected To reelect Yohanan Engelhardt as a Class III director.
“Nominee For Against Abstain Broker Non-Votes Yohanan Engelhardt 5,657,555 10,593,238 406,934 13,704,575”
Wayne B. Weisman departed as Director at Lifeward Ltd..
“the previously announced decision of Aryeh (Arik) Dan and Wayne B. Weisman, current Class III directors of the Board, not to stand for re-election at the Annual Meeting.”
Aryeh (Arik) Dan departed as Director at Lifeward Ltd..
“the previously announced decision of Aryeh (Arik) Dan and Wayne B. Weisman, current Class III directors of the Board, not to stand for re-election at the Annual Meeting.”
Yasushi Ichiki resigned as Director at Lifeward Ltd..
“On September 4, 2023, Yasushi Ichiki, a current Class I director of the Board of Directors (the “Board”) of ReWalk Robotics, Ltd. (the “Company”), notified the Board that, in order to further the Company’s previously-announced policy of routinely refreshing the composition of the Board, he intends to resign from the Board immediately following the Company’s 2023 Annual General Meeting of Shareholders (the “Annual Meeting”).”
Lifeward Ltd. completed an acquisition involving AlterG, Inc. for $19 million in cash (closed 2023-08-11).
“AlterG became an indirect and wholly owned subsidiary of the Company. The aggregate consideration paid by RRI at the Closing pursuant to the Agreement was approximately $19.0 million in cash (subject to customary adjustments for net working capital, indebtedness, cash, and transaction expenses). Following the Closing, the Agreement provides for two potential”
Lifeward Ltd. entered into Agreement and Plan of Merger with AlterG, Inc. valued at approximately $19.0 million in cash (effective 2023-08-08).
“On August 8, 2023, ReWalk Robotics, Inc. (“RRI”), a wholly owned subsidiary of ReWalk Robotics Ltd. (the “Company”), entered into an Agreement and Plan of Merger (the “Agreement”) with AlterG, Inc. (“AlterG”), Atlas Merger Sub, Inc., a wholly owned subsidiary of RRI (“Merger Sub”), and Shareholder Representative Services LLC, solely in its capacity as representative, agent and attorney-in-fact of the securityholders of AlterG, pursuant to which, Merger Sub will merge with and into AlterG, with AlterG continuing as the surviving corporation and a wholly owned subsidiary of RRI (the “Acquisition”).”
Wayne B. Weisman departed as Director at Lifeward Ltd..
“Aryeh (Arik) Dan and Wayne B. Weisman, current Class III directors of the Board of Directors (the “Board”) of ReWalk Robotics, Ltd. (the “Company”), notified the Board that, in order to further the Company’s previously-announced policy of routinely refreshing the composition of the Board, they will not stand for reelection at the Company’s 2023 Annual General Meeting of Shareholders (the “Annual Meeting”).”
Aryeh (Arik) Dan departed as Director at Lifeward Ltd..
“Aryeh (Arik) Dan and Wayne B. Weisman, current Class III directors of the Board of Directors (the “Board”) of ReWalk Robotics, Ltd. (the “Company”), notified the Board that, in order to further the Company’s previously-announced policy of routinely refreshing the composition of the Board, they will not stand for reelection at the Company’s 2023 Annual General Meeting of Shareholders (the “Annual Meeting”).”
Lifeward Ltd. reported the three months ended March 31, 2023 results: revenue $1.2 million, net income $4.3 million.
“announced its financial results for the three months ended March 31, 2023. Highlights of the first quarter of 2023 include: • Total revenue for the first quarter of 2023 was $1.2 million, as compared to $0.9 million in the first quarter of 2022, up 40%; • Gross margin was 46.4% in Q1’23, as compared to 30.3% in Q1’22, a 16 percentage point increase; • Operating”
Lifeward Ltd. reported the fiscal year ended December 31, 2022 results: revenue $5.5 million, net income $19.6 million net loss.
“Annual revenue was $5.5 million in 2022 compared to $6.0 million in 2021.”
Lifeward Ltd. reported the fourth quarter of 2022 results: revenue $2.2 million, net income $5.3 million net loss.
“Revenue was $2.2 million in the fourth quarter of 2022, an increase of 75% as compared to $1.2 million during the fourth quarter of 2021.”
Lifeward Ltd. reported the third quarter ended September 30, 2022 results: revenue $0.9 million, net income $5.5 million dollars.
“to Medicare Administrative Contractors (MACs) for Coverage and Reimbursement of the ReWalk Exoskeleton for Medicare Beneficiaries As of November 4 th , ReWalk Has Repurchased $0.9 Million of Common Stock Since Initiation of Its Program German Federal Social Court Hearing on November 10 th with Ruling Expected Shortly After MARLBOROUGH, Mass. BERLIN, Germany and”
Michael A. Lawless was appointed as Chief Financial Officer at Lifeward Ltd..
“appointed Michael A. Lawless to serve as the Company’s Chief Financial Officer and Principal Financial Officer effective as of September 19, 2022”
Joseph Turk was appointed as Class I Director at Lifeward Ltd..
“appointed Mr. Joseph Turk as a Class I Director of the Company to serve until the 2024 annual general meeting of shareholders, with such appointment to take effect on April 20, 2022.”
Almog Adar was appointed as Principal Financial Officer and Principal Accounting Officer at Lifeward Ltd..
“the Board of Directors of the Company appointed Almog Adar, the Company’s Director of Finance and Corporate Financial Controller, to serve as the Company’s Principal Financial Officer and Principal Accounting Officer for Securities and Exchange Commission purposes, effective as of March 12, 2022.”
Ori Gon resigned as Chief Financial Officer at Lifeward Ltd..
“Ori Gon, the Company’s former Chief Financial Officer, and Principal Financial Officer and Principal Accounting Officer resigned from the Company, effective March 12, 2022.”
Ori Gon departed as Chief Financial Officer at Lifeward Ltd..
“On December 13, 2021, Ori Gon, the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of ReWalk Robotics Ltd. (the “Company”) informed the Company that he intends to resign from the Company, effective March 12, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.